Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors

por Polonsky, William H, Henry, Robert R
Publicado 2016

SGLT inhibitor adjunct therapy in type 1 diabetes

por McCrimmon, Rory J., Henry, Robert R.
Publicado 2018

Signals and Noise in Drug Safety Analyses: The incretin therapy debate provides the rationale for revamping epidemiologic pharmacovigilance

por Cefalu, William T., Rosenstock, Julio, Henry, Robert R., Riddle, Matthew
Publicado 2013

Myokine Regulation of Insulin Secretion: Impact of Inflammation and Type 2 Diabetes

por Ryan, Alexander J., Ciaraldi, Theodore P., Henry, Robert R.
Publicado 2020

Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study

por Henry, Robert R., Klein, Eric J., Han, Jenny, Iqbal, Nayyar
Publicado 2016

Altered Myokine Secretion Is an Intrinsic Property of Skeletal Muscle in Type 2 Diabetes

por Ciaraldi, Theodore P., Ryan, Alexander J., Mudaliar, Sunder R., Henry, Robert R.
Publicado 2016

Adipose tissue depot and cell size dependency of adiponectin synthesis and secretion in human obesity

por Meyer, Lauren K, Ciaraldi, Theodore P, Henry, Robert R, Wittgrove, Alan C, Phillips, Susan A
Publicado 2013

Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes

por Henry, Robert R., Rosenstock, Julio, Logan, Douglas K., Alessi, Thomas R., Luskey, Kenneth, Baron, Michelle A.
Publicado 2013

Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes

por Eckel, Robert H., Henry, Robert R., Yue, Patrick, Dhalla, Arvinder, Wong, Pamela, Jochelson, Philip, Belardinelli, Luiz, Skyler, Jay S.
Publicado 2015

Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placeb...

por Polidori, David, Sha, Sue, Mudaliar, Sunder, Ciaraldi, Theodore P., Ghosh, Atalanta, Vaccaro, Nicole, Farrell, Kristin, Rothenberg, Paul, Henry, Robert R.
Publicado 2013

Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials

por Henry, Robert R., Müller‐Wieland, Dirk, Taub, Pam R., Bujas‐Bobanovic, Maja, Louie, Michael J., Letierce, Alexia, Ginsberg, Henry N.
Publicado 2018

Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial

por Henry, Robert R., Strange, Poul, Zhou, Rong, Pettus, Jeremy, Shi, Leon, Zhuplatov, Sergey B., Mansfield, Traci, Klein, David, Katz, Arie
Publicado 2018

A Pilot Study to Assess Clinical Utility and User Experience of Professional Continuous Glucose Monitoring Among People With Type 2 Diabetes

por Midyett, Kurt, Unger, Jeffrey R., Wright, Eugene E., Daniel, Timothy D., Kruger, Davida F., Henry, Robert R., Hegazi, Refaat A.
Publicado 2019

Activation of G proteins by GIV-GEF is a pivot point for insulin resistance and sensitivity

por Ma, Gary S., Lopez-Sanchez, Inmaculada, Aznar, Nicolas, Kalogriopoulos, Nicholas, Pedram, Shabnam, Midde, Krishna, Ciaraldi, Theodore P., Henry, Robert R., Ghosh, Pradipta
Publicado 2015

Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized tria...

por Henry, Robert R., Frias, Juan P., Walsh, Brandon, Skare, Sharon, Hemming, John, Burns, Colleen, Bicsak, Thomas A., Baron, Alain, Fineman, Mark
Publicado 2018

Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes

por Mudaliar, Sunder, Armstrong, Debra A., Mavian, Annie A., O’Connor-Semmes, Robin, Mydlow, Patricia K., Ye, June, Hussey, Elizabeth K., Nunez, Derek J., Henry, Robert R., Dobbins, Robert L.
Publicado 2012

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies

por Colhoun, Helen M., Ginsberg, Henry N., Robinson, Jennifer G., Leiter, Lawrence A., Müller-Wieland, Dirk, Henry, Robert R., Cariou, Bertrand, Baccara-Dinet, Marie T., Pordy, Robert, Merlet, Laurence, Eckel, Robert H.
Publicado 2016

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high card...

por Müller-Wieland, Dirk, Leiter, Lawrence A., Cariou, Bertrand, Letierce, Alexia, Colhoun, Helen M., Del Prato, Stefano, Henry, Robert R., Tinahones, Francisco J., Aurand, Lisa, Maroni, Jaman, Ray, Kausik K., Bujas-Bobanovic, Maja
Publicado 2017

Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial

por Leiter, Lawrence A., Cariou, Bertrand, Müller‐Wieland, Dirk, Colhoun, Helen M., Del Prato, Stefano, Tinahones, Francisco J., Ray, Kausik K., Bujas‐Bobanovic, Maja, Domenger, Catherine, Mandel, Jonas, Samuel, Rita, Henry, Robert R.
Publicado 2017

Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial

por Ray, Kausik K., Leiter, Lawrence A., Müller‐Wieland, Dirk, Cariou, Bertrand, Colhoun, Helen M., Henry, Robert R., Tinahones, Francisco J., Bujas‐Bobanovic, Maja, Domenger, Catherine, Letierce, Alexia, Samuel, Rita, Del Prato, Stefano
Publicado 2018